TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06723444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning and Memory Training
Description: The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
Study: NCT06726382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine Nasal Spray
Description: 1 x 28 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 x 5,6 ml p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 x 5,6 ml p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 x 5,6 ml p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat 150 MG
Description: 1 x 150 mg tablet
Study: NCT06725420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided local Injection
Description: Ultrasound-Guided steroid injection and splinting in patients with carpal tunnel syndrome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Steroid Injection
Description: Intramuscular gluteal steroid injection and Splinting in Patients With Carpal Tunnel Syndrome

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splinting
Description: wrist night splint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splinting
Description: wrist night splint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splinting
Description: wrist night splint
Study: NCT06727422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin 66mg + N-acetylcysteine 560mg three times daily
Description: RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Description: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo three times daily
Study: NCT06726369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6204 (SKB535) for Injection
Description: MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT06727279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized food - Plant-Based Meat Analog
Description: Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard isocalorie diet
Description: Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
Study: NCT06725992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NS250
Description: Ilaprazole 20mg + Sodium bicarbonate 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NS250
Description: Ilaprazole 20mg + Sodium bicarbonate 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-SR
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-SR
Description: Ilaprazole 10mg
Study: NCT06726356

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoalveolar Lavage
Description: Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage
Description: Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
Study: NCT06726252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR measurement and intravascular imaging
Description: Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement, and intravascular imaging, including IVUS and integrated OCT-IVUS using a single cathete to assess the accurary of OUFR, using wire-based FFR measurement as the gold standard.
Study: NCT06725628

Intervention type: DIAGNOSTIC_TEST
Intervention: Thy_CLNM_multi_omics
Description: Surgery
Study: NCT05551273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT06126315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine
Description: Acetyl-l-carnitine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine
Description: Acetyl-l-carnitine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06656663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Prescribing
Description: SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Signposting
Description: Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
Study: NCT06590961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX-303061
Description: UBX-303061 oral dosage
Study: NCT05488067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral atorvastatin treatment for ALGS children with xanthoma
Study: NCT06456749

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Disease Management
Description: For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
Study: NCT06121986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Ketogenic Nutrition Adherence Program
Description: Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Ketogenic Nutrition Adherence Program
Description: Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Nutrition Adherence Program
Description: Participants will be provided with education, support, and resources for following a Mediterranean diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Nutrition Adherence Program
Description: Participants will be provided with education, support, and resources for following a Mediterranean diet.
Study: NCT05510037

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was needed

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was needed

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was needed
Study: NCT05124470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation by musical training sessions
Description: The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises.
Study: NCT05751213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knack technique.
Description: It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle exercises
Description: It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercises
Description: It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
Study: NCT05402527

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study: NCT04998669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.
Study: NCT05402527

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study: NCT06725615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Umami exposure
Description: This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Umami exposure
Description: This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
Study: NCT05780242

Intervention type: BEHAVIORAL
Intervention: Self-questionnaire Eating Attitudes
Description: self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa

Intervention type: BEHAVIORAL
Intervention: Situational Anxiety and Trait Anxiety
Description: assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation

Intervention type: BEHAVIORAL
Intervention: Beck Depression Inventory (BDI) scale
Description: a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents

Intervention type: BEHAVIORAL
Intervention: • Post-traumatic Check List Scale
Description: questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
Study: NCT04722640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKYRIZI
Description: SKYRIZI
Study: NCT04734340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP setting
Description: Ventilator parameter setting by EIT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ARDS-net PEEP setting
Description: Ventilator parameter setting according to ARDS-net table
Study: NCT06660004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Experimental 1 Creatine HCl
Description: Creatine hcl

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Experimental 2 Creatine HCl
Description: Creatine hcl
Study: NCT04889378

Intervention type: OTHER
Intervention: prehabilitation
Description: very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
Study: NCT06370884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMT
Description: a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
Study: NCT05476809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smart-cloth assisted home nursing
Description: The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
Study: NCT06565845

Intervention type: PROCEDURE
Intervention: Surgery
Description: patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.

Intervention type: PROCEDURE
Intervention: Surgery
Description: patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.

Intervention type: DRUG
Intervention: triple anti-tuberculosis drug
Description: Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).

Intervention type: DRUG
Intervention: triple anti-tuberculosis drug
Description: Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
Study: NCT06283056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device treatment
Description: InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
Study: NCT05188274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T92
Description: T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo matched to T92 granules will be taken BID for 8 weeks.
Study: NCT06725615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Umami exposure
Description: This group will receive the basic diet without added MSG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one-week run-in period
Description: During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one-week run-in period
Description: During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one-week run-in period
Description: During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
Study: NCT06726460

Intervention type: DIAGNOSTIC_TEST
Intervention: Nova Stat Profile pHOx Ultra Analyzer System(Nova)
Description: This group involves the use of Nova for measuring serum and whole blood samples. The results from Nova will be compared with those obtained from P1.
Study: NCT06660004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Experimental 3 Creatine Ethyl ester
Description: Creatine ethyl ester

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: Experimental 4 Placebo
Description: Placebo
Study: NCT04822467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ53 Wipe
Description: SQ53-based wipe to be used by the participant daily or upon dressing change

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol Wipe
Description: Ethanol-based wipe to be used by the participant daily or upon dressing change
Study: NCT06726460

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel POCT dry electrolyte analysis system(P1)
Description: This group involves the use of P1 for measuring serum and whole blood samples. The results from P1 will be compared with those obtained from Nova.
Study: NCT05639257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine tablets increasing dosis to maximal 300 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Namuscla
Description: Namuscla tablets increasing dosis to maximal 501 mg daily
Study: NCT05830786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR)
Description: Using Oculus Quest 2 (Reality Labs, Meta Platforms, United States) headsets the PrecisionOS platform version 3.0 (PrecisionOS Technology, Canada) virtual reality surgical modules will be utilized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional hands on orthopaedic workshop group
Description: Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
Study: NCT06092801

Intervention type: OTHER
Intervention: No intervention
Description: No intervention